GT Biopharma, Inc. — 2015 Form 10-K summary
Entity and period: The request identifies GT Biopharma, Inc., but the supplied filing is for OXIS International, Inc. It reports the fiscal year ended December 31, 2015, with 2014 comparative figures. The summary below reflects the supplied OXIS filing and does not assume the entities are the same.
Business context and reporting period
OXIS describes itself as an immuno-oncology company developing cancer therapeutics through its subsidiary, Oxis Biotech. Its disclosed programs include OXS-1550, a CD19/CD22-targeted candidate that had reached early human clinical trials; OXS-2175 for triple-negative breast cancer and OXS-4235 for multiple myeloma, both described as preclinical candidates. The company had two employees at year-end and relied substantially on consultants and third-party manufacturers.
Financial performance and position
| Metric | 2015 | 2014 |
|---|---|---|
| Total revenue | $27,000 | $61,000 |
| Operating expenses | $8.954 million | $2.400 million |
| Loss from operations | $8.927 million | $2.396 million |
| Change in warrant and derivative liabilities | $6.760 million expense | $15.963 million expense |
| Interest expense | $17.039 million | $5.146 million |
| Net loss | $32.726 million | $23.489 million |
| Basic and diluted loss per share | $13.67 | $10.09 |
| Cash and cash equivalents at year-end | $47,000 | $855,000 |
- 2015 revenue comprised $27,000 of license revenue and no product revenue; 2014 included $33,000 of license revenue and $28,000 of product revenue. The filing says products were not actively marketed in 2015 as the company shifted toward biotech development.
- Gross profit was $27,000 in 2015 and $4,000 in 2014. A gross-margin comparison is not especially informative given the minimal revenue and no 2015 product sales.
- Research and development expense was $1.000 million in 2015 versus zero in 2014; selling, general and administrative expense was $7.954 million versus $2.400 million. The MD&A narrative describes the full $8.954 million operating-expense total as SG&A, while the audited statements classify $1.000 million as R&D.
- Net cash used in operating activities was $4.657 million, compared with $1.749 million in 2014. Investing activities used $1,000; financing activities provided $3.850 million. Cash declined by $808,000 during 2015.
- At year-end, current assets were $49,000 and current liabilities $61.174 million, producing a $61.125 million working-capital deficit. Total liabilities were $61.888 million, including a $44.531 million warrant liability; stockholders’ deficit was $61.834 million. Accumulated deficit was $145.682 million.
- The filing reports 12,525,721 warrants outstanding at year-end, with a weighted-average exercise price of $1.25. Convertible debt and warrants carry substantial potential dilution.
Material changes, outlook and risks
- Year-over-year: Revenue fell $34,000 and net loss increased $9.237 million. Higher operating costs and interest expense more than offset the lower derivative revaluation expense. The company attributed the interest increase to additional notes and allonges.
- Financing and liquidity: Management said additional capital was needed by the end of the next quarter to continue operations and estimated it would need approximately $4–5 million over the next twelve months to fund operations and pay current liabilities. It was pursuing equity or debt financing but gave no assurance it could obtain funding.
- Going concern: The auditor’s report highlights substantial doubt about OXIS’s ability to continue as a going concern because of recurring losses and dependence on future financing and successful operations. The financial statements include no adjustments for the potential effects of a failure to continue.
- Debt and dilution: During 2015, OXIS issued multiple 10% convertible debentures and warrants. Anti-dilution adjustments reduced certain conversion prices to $1.25. Allonges issued following defaults under share-reservation and other agreements increased note principal. The filing also describes older debt defaults and creditor remedies, with a December 2015 forbearance agreement covering certain 2006 debentures.
- Subsequent events: January 2016 restructuring agreements contemplated converting approximately $15.056 million of debt at $1.25 per share, exchanging preferred stock for 4.075 million common shares, and exchanging warrants for common shares, subject in key parts to successful completion of a $6 million financing. The filing says the arrangements could result in up to 28,389,193 shares. It also reports later share issuances for warrant cancellations, consulting services and executive contractual rights; timing and relationship of these disclosures should be checked against the complete filing and subsequent filings.
- Development and execution risks: Drug candidates require further development and regulatory approvals, which may require substantial time and funding. OXIS relied on a small number of contract manufacturers and had no long-term manufacturing agreements. Its risk-factor section was omitted under the smaller-reporting-company exemption, so the filing provides no detailed Item 1A risk-factor list.
- Controls and governance: Management concluded disclosure controls and internal control over financial reporting were ineffective at December 31, 2015, citing lack of segregation of duties and risk of executive override due to the small staff and reliance on consultants. Neither of its two directors was considered independent.
- Contingencies and unusual items: A 2015 consulting-contract dispute was settled for $150,000 in cash and 11,429 restricted shares. OXIS also recorded significant noncash derivative and interest-related charges. It reported no off-balance-sheet arrangements at year-end.
Most important facts for investors to verify
- Whether OXIS obtained sufficient financing to meet near-term obligations, and how much cash and debt remained after year-end.
- Whether the proposed restructuring’s $6 million financing condition was met, the final shares issued, and the resulting fully diluted share count.
- The current status, maturity, default terms and conversion mechanics of outstanding debt, including allonges, anti-dilution provisions and warrant liabilities.
- The actual clinical and regulatory status of each candidate, the terms and continuing obligations of its licenses, and the funding required to advance development.
- Whether management remediated the reported material weaknesses and whether subsequent filings address the going-concern uncertainty.
- Whether the supplied OXIS filing is the intended filing for the company identified in the request as GT Biopharma, Inc.